Quick Read
-
KYTX dropped 12% after JPMorgan trimmed its price target to $29, despite beating Q1 estimates and initiating a rolling BLA for miv-cel targeting a 2027 launch.
-
BEAM slid 8% from a 52-week high and ALLO dropped 5%, while myasthenia gravis rival RNAC held up best, falling only 1%.
-
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Kyverna Therapeutics didn't make the cut. Grab the names FREE today .
Shares of Kyverna Therapeutics( NASDAQ:KYTX ) are down almost 13% in Friday afternoon trading, changing hands near $8.60 after opening the session at $9.81. The pullback interrupts a strong run for the clinical-stage autoimmune CAR-T developer, which is still up 25% over the past month and 215% over the past year.
Analyst Target Cut Cools a Hot Trade
The catalyst appears to be a fresh analyst note. JPMorgan reiterated its Overweight rating but trimmed its price target on the stock to $29, while Weiss Ratings and Wall Street Zen issued sell calls. The consensus still sits at Moderate Buy with an average target of $30, but the reset in expectations is landing hard on a stock that had tripled off last summer's lows.
The move is notable because it comes despite reasonable results for a clinical-stage biotech. Kyverna reported a Q1 2026 loss of -$0.66 per share, better than the -$0.73 consensus. The company also initiated a rolling BLA submission for lead asset miv-cel in stiff person syndrome, with completion expected Q4 2026 and potential commercial launch in 2027. CEO Warner Biddle called the FDA alignment on a single-arm trial "a significant milestone" in the company's May filing.
Kyverna Therapeutics (KYTX) stock experienced a significant drop on Friday afternoon, influenced by analyst target cuts despite the company's strong Q1 2026 earnings and ongoing progress toward BLA submission.
Act now:the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Kyverna Therapeutics didn't make the cut. Grab the names FREE today .
Cell-Therapy Peers Also Under Pressure
The broader autoimmune and oncology cell-therapy group is soft on the session alongside Kyverna. Cabaletta Bio( NASDAQ:CABA ), which recently raised $150 million with Eli Lilly participating, is off 4%. Allogene Therapeutics( NASDAQ:ALLO ), fresh off strong ALPHA3 data earlier this summer, is down 5%. Beam Therapeutics( NASDAQ:BEAM ) is the weakest of the group, sliding 8% from a recent 52-week high. Cartesian Therapeutics( NASDAQ:RNAC ), Kyverna's most direct competitor in myasthenia gravis, is holding up better, down only 1%.
After a month in which Kyverna joined the Russell 2000 and Russell 3000 indexes, hired a new CFO and Chief Legal Officer, and drew a 33.3% stake increase from AIGH Capital, expectations had run ahead of the setup. A single price-target trim was enough to trigger profit-taking in a low-float, high-beta name. Kyverna's beta sits at 1.88, and shares still trade well below the 52-week high of $13.67.
What to Watch
The next scheduled catalyst is Q2 2026 earnings on August 11, 2026, with consensus at -$0.67. Before then, investors will look for updates on the rolling BLA submission for miv-cel and longer-term Phase 2 gMG follow-up data guided for H2 2026. I would keep an eye on whether KYTX can hold the $8.72 50-day moving average into the close.
Act now:the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Kyverna Therapeutics didn't make the cut. Grab the names FREE today .
Contact editorial@247wallst.com for any questions or corrections.
